Actively Recruiting

Age: 1Year +
All Genders
ID02688517

Targeted Genomic Analysis of Human Cancers

Led by Rutgers, The State University of New Jersey · Updated on 2026-04-17

1100

Participants Needed

11

Research Sites

N/A

Total Duration

On this page

Sponsors

R

Rutgers, The State University of New Jersey

Lead Sponsor

N

National Cancer Institute (NCI)

Collaborating Sponsor

AI-Summary

What this Trial Is About

Researchers are studying targeted genomic analysis of blood and tissue samples from patients with cancer, focusing on rare cancers with poor prognosis or limited treatment options. This observational research aims to identify genetic changes using genomic sequencing to help understand cancer development and to provide clinicians with mutation data that may guide treatment or referral to relevant studies. The study also collects clinical outcomes and tumor genome data for future analysis and cancer model development. The study involves analyzing previously collected tumor tissue samples using next-generation sequencing to detect mutations. Patients may also provide blood samples for analysis of circulating cell-free DNA and circulating tumor cells. These procedures support the identification of actionable mutations that may have available targeted therapies. The research includes correlative laboratory biomarker analysis. Participants are followed after study completion every 3 months for 2 years, then every 6 months for up to 15 years to monitor clinical outcomes and mutation frequencies. Researchers measure the frequency of specific mutations and the rate of actionable mutations in rare or poor prognosis cancers over this period. This long-term follow-up helps correlate genomic findings with patient outcomes and supports future research developments.

CONDITIONS

Brief Title

Targeted Genomic Analysis of Blood and Tissue Samples From Patients With Cancer

Who Can Participate

Age: 1Year +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Karnofsky or Lansky performance score of 30 or higher
  • Signed written informed consent
  • Evaluation in oncology or radiology clinic with biopsy-confirmed rare cancer or cancer with poor prognosis
  • Priority given to rare cancers with poor prognosis and lack of effective standard therapy
  • Availability and accessibility of paraffin tumor tissue blocks for analysis
Not Eligible

You will not qualify if you...

  • Karnofsky or Lansky performance score less than 30
  • Life expectancy less than 3 months

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Your Study Journey

Screening

Duration - 2 to 4 weeks

Participants are screened for eligibility to participate in the trial.

1 visit (in-person)

Diagnostic Evaluation

Duration - Up to 1 week

Participants provide previously collected tumor tissue samples and may undergo blood sample collection for genomic analysis.

1 visit (in-person) for blood sample collection; tissue samples are previously collected

Long-term Monitoring

Duration - Up to 15 years

Participants are followed up to collect clinical outcomes and monitor genomic data every 3 months for 2 years, then every 6 months for up to 15 years.

Follow-up visits every 3 months for 2 years, then every 6 months for up to 15 years

Trial Site Locations

Total: 11 locations

1

Ocean Medical Center

Brick, New Jersey, United States, 08724

Completed

2

Bayshore Community Hospital

Holmdel, New Jersey, United States, 07733

Completed

3

RWJBarnabas Health - Jersey City Medical Center, Jersey City

Jersey City, New Jersey, United States, 07302

Actively Recruiting

4

Southern Ocean County Medical Center

Manahawkin, New Jersey, United States, 08050

Completed

5

Morristown Medical Center

Morristown, New Jersey, United States, 07960

Completed

6

Jersey Shore Medical Center

Neptune City, New Jersey, United States, 07753

Completed

7

Rutgers Cancer Institute of New Jersey

New Brunswick, New Jersey, United States, 08903

Actively Recruiting

8

Riverview Medical Center/Booker Cancer Center

Red Bank, New Jersey, United States, 07701

Completed

9

Riverview Medical Center

Red Bank, New Jersey, United States, 07701

Active, Not Recruiting

10

Overlook Hospital

Summit, New Jersey, United States, 07902

Completed

11

University of Wisconsin Hospital and Clinics

Madison, Wisconsin, United States, 53792

Withdrawn

Loading map...

Research Team

C

Clinical Trials Office

How is the study designed?

Study Type

OBSERVATIONAL

Masking

N/A

Allocation

N/A

Model

N/A

Primary Purpose

N/A

Number of Arms

1

Similar Trials

18F-FAPIBiotin PET/CT Dosimetry and Biodistribution Study in...

Malignant Neoplasm

Actively Recruiting

1 location

The Diagnostic Efficiency of 68Ga-FAPI PET/CT in Malignant T...

Fibroblast Activation Protein Inhibitor

Actively Recruiting

1 location

68Ga-JH04 PET/CT Dosimetry and Biodistribution Study in Pati...

Malignant Neoplasm

Actively Recruiting

1 location

Frequently Asked Questions

Have more questions? Get in touch with our team for quick support

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here